Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas.

A clinical trial, NCT06498648, is currently underway to test the effectiveness and safety of combining the anti-cancer drug abemaciclib with the chemotherapy treatment gemcitabine for patients with soft tissue sarcoma. The trial aims to determine the side effects and optimal dosage of abemaciclib, as well as compare its effectiveness to the standard treatment of gemcitabine with docetaxel. Abemaciclib works by blocking a protein that signals tumor cells to multiply, while gemcitabine blocks DNA production in cells. The trial will assess various outcome measures, including progression-free survival and overall survival. The trial is open to individuals with advanced or metastatic soft tissue sarcoma, leiomyosarcoma, or dedifferentiated liposarcoma, and is expected to be completed by October 1, 2026. [Extracted from the article]